+917069000000 info@cims.org

DR. SATYA GUPTA

Dr. Satya Gupta

Dr. Satya Gupta

Dr. Satya Gupta

Interventional Cardiologist

MD, DM (CARDIOLOGY), FIC, FACC, FESC

Cardiology

satya.gupta@cims.org

+91 9925045780

CURRICULUM – VITAE

Name: Dr. Satya Gupta

Date of Birth:            21st May 1970

Address: Office:

                                   Care Institute of Medical Science (CIMS)

                                   Off Science City Road, Opp Sukan Mall

                                   Near Sola Bridge

                                   Ahmedabad-380 054, India

                                   Phone: +91-79-27712771(1-5 lines)

            Fax :    +91-79-27712770                                  

Email:                       satya.gupta@cims.me

CURRENT AFFILIATION:

Consultant and Interventional Cardiologist at CIMS hospital Ahmedabad                                      

Qualification

College / University

Year

FIC (Cardiology)

DM (Cardiology)

MD(Internal medicine)

Internship

MBBS

USMLE

Pitie-Salpetriere University Hospital, Paris

Christian Medical College, Vellore,

University of Rajasthan, Jaipur

University of Rajasthan, Jaipur

University of Rajasthan, Jaipur

ECFMG, Philadelphia, USA

July 2006

August 2005

June 1999

Mar1994 – Feb 1995

Feb 1994

Passed in 1996


Work Experience:

  • Fellow in Interventional Cardiology: PITIE-SALPETRIERE University Hospital Paris, France – Nov 2005 – June 2006.

  • Clinical Visiting Scientist for Multislice CT angiography and Intravascular Ultrasound: Cardiovascular Center Aalst, OLV Ziekenhus, Aalst, Belgium – 6th – 16th    June 2006.

  • DM Trainee and Tutor in CardiologyChristian Medical College Hospital, Vellore – since January 2002- Oct 2005.

  • Senior RegistrarDept. Of cardiology – Christian Medical College Hospital, Vellore – February 2000 – January 2002

  • Senior RegistrarJaslok Hospital and Research Center, Mumbai –         August 1999 – November 1999

  • Registrar – Dept. of Medicine – Dr. S.N Medical College, Jodhpur –              March 1996 – June 1999

  • Medical officer – Kamla Nagar Hospital, Jodhpur – March 1995- February 1996

Publications: (Index Jour)

  • “Impact of anticoagulation on Ionic and Non Ionic Contrast Media effect on thrombogenesis and fibrinolysis: The PEPCIT Study” Sent to Arteriosclerosis, Thrombosis and Vascular Biology Journal for publication.
  • Trans-radial Interventions: Our Experience. Indian Heart J 2010; 62:264-266.

  • Tips and Tricks for Radial Interventions. Indian Heart J 2010; 62:275-276.

  • Recanalization of single functioning kidney (Case report). Indian Heart J 2005; 57:741-743.

  • Mortality and morbidity due to acute ST segment elevation myocardial infarction in the current era. Indian Heart J 2004; 56:210-214.

  • Prevalence of coronary artery disease in patients with rheumatic heart disease. Indian Heart J 2004; 56:129-131.

  • Blood filled cysts of heart. Indian Heart J 2004; 56:174-175.

  • Heart failure: What proportion of patients satisfies the Electrocardiographic criteria for cardiac resynchronization therapy? Indian Heart J 2003; 55:619-623.

  • Utility of N-Terminal Pro BNP in the diagnosis of heart failure. Indian Heart J 2003; 55:35-39.

  • Affect of plasmodium falciparum and plasmodium vivax infection on renal functions. SDMH Jour (ISSN 0970-0390) 1998; 22:53-58

  • Pulmonary Pulsus Alternans: An Unusual pulmonary haemodynamic phenomenon in patients with mitral stenosis. Sent to Cathet Cardiovasc Interv for publication.

Presentations in Conferences:

  • Effect of ionic and non ionic constrast media on thrombegenis and fibrinolysis depends on anticoagulation regimens. Presented at European society of cardiology conference, Vienna, Austria on 4rd Sept 2007. European Heart Journal (2007 ) 28 ( Abstract Supplement ), 665. http://spo.escardio.org/abstract-book/presentation.aspx?id=52919

  • Profile of Myocardial Infarction in Young Indian Patients. Indian Heart J 2004; 56:406.

  • In-hospital mortality and complications due to acute STEMI in patients with previous myocardial infarction. Indian Heart J 2004; 56:406.

  • Profile of coronary artery disease in Indian women. Indian Heart J 2004; 56:407.

  • Target lipid levels and Statins. Indian Heart J 2004; 56:557.

  • Comparison of echocardiographic left ventricular dimension with plasma levels of NTpro BNP. Presented at 9th Annual conference of Indian academy of echocardiography and international conference on advances in cardiology. 13th-15th Feb 2004, Bhubaneswar.

  • In hospital mortality and 30-day events in patients with acute STEMI presenting to a tertiary care center. Indian Heart J 2003;55:462

  • Role of NTpro BNP for the diagnosis of LV systolic and diastolic dysfunction. Indian Heart J 2003;55:466

  • Cutting balloon angioplasty of obstructive lesions in Takayasu’s arteritis yields exceptional results. Indian Heart J 2003;55:476

  • Frequency of angiographic ally significant CAD in patients with RHD. Indian Heart J 2003; 55:578

  • Components of pre-hospital delay in acute myocardial infarction. Indian Heart Journal 2002; 54:481.

  • Utility of N-Terminus of the Precursor Brain Natriuretic Peptide in identifying left ventricular dysfunction. Indian Heart Journal 2002; 54:559.

  • Gender differences in exercise electrocardiogram using Bruce Protocol. Indian Heart Journal 2002; 54:626.

  • Renal artery involvement in patients with coronary artery disease. Indian Heart Journal 2001; 53:573.

  • Serum Troponin –T in the diagnosis of acute myocardial infarction and its comparison with CPKMB. [Presented at IX annual conference, Association of Physician of India, (Rajasthan Chapter) 1998]

  • “Liver involvement in falciparum malaria” A biochemical and histopathological analysis. 54th Joint Annual National Conference of association of physician of India. JAPI 1999; 47:27.

Conferences Attended:

  • 5 Days Hands on workshop for complex PCI at Marseille France, July 2011.

  • European Society of Cardiology Conference. 2009 Aug29-2 Sept, Barcelona, Spain.

  • The 5th World Congress of Pediatric Cardiology and Cardiac Surgery. 2009 June 21-26, Cairns, Australia.

  • European Society of Cardiology Conference. 2008 Sept 1-4, Munich, Germany.

  • Annual Conference of Pediatric Cardiac Society of India. 2004, 2008.

  • Kamakura Live Radial Workshop, Yokohama, Japan, Dec 2007.

  • Newer Advances in Interventional Cardiology. Symposium at Kuala Lumpur, Malaysia 23-26 June 2007

  • World Congress of Cardiology 2006 and Joint Meeting of European Society of Cardiology & World Heart Federation, 2-6th Sept, Barcelona, Spain.

  • EuroPCR 2006, 16-19th May 2006, Paris, France.

  • Thrombosis & Urgences Coronaires, 30-31st March Paris, France.

  • French Society of Intervention Cardiology Congress( High Tech 2006), 25-27th Jan 2006, Marseille, France.

  • CSI, Annual Conference:- 2001,2002,2003,2004,2008.

Work experience in Cardiology:

After finishing MD in internal medicine I worked at Jaslok Hospital and Research Center Mumbai, which is one of the premier hospitals of India. During this period I was exposed to manage critically ill patients and learned the interventional procedures require managing such patients.

In February 2000, I joined Department of Cardiology, Christian Medical College and Hospital Vellore, as a Senior Registrar. This period involved training and care of adult and pediatric cardiac patients. Apart from supervised care of out and inpatients, it also involved management of patients in cardiac care unit, performing special investigations like treadmill stress testing.

Subsequently, I joined the same institute as a DM trainee in Cardiology under MGR Medical University. This 3 year period involve care of out and inpatients, performing special investigations independently viz. treadmill stress test, holter analysis, echocardiography, cardiac catheterization and interventions. During active posting in cardiac catheterization lab for 7 months, I was doing various diagnostic cardiac catheterization procedures independently and assisted various cardiac interventions.

While going through basic cardiology training, I realized that cardiology is vast and I discovered that, I am more comfortable and competent in doing the interventional procedures as well as I find my inclination toward academics. To further my knowledge in the academics and interventions, I selected PITIE-SALPETRIERE University Hospital Paris (France) as my destination to advance my career.

Pitie-Salpetriere is the largest and oldest Hospital (founded in 1613) in Europe till date. Here I had honor to work with Dr Gilles Montalescot who is renowned for his contribution in the field of cardiology. Dr Gilles trained me for radial angiograms and angioplasties and also participated in ongoing multinational research projects. I performed hundreds of radial angiograms and angioplasties independently under the guidance of Prof Gilles Montalescot.

In July 2006, I joined the leading cardiac group in Ahmedabad which is know for providing best cardiac services in the country. I was also affiliated with V S General Hospital as a consultant cardiologist from July 2006 to August 2008. I am performing all cardiac procedure independently, confidently and sincerely because of the excellent training I received from masters in the field of cardiology. Details of cardio logical procedures performed by me as on 31st August 2010 are as follow.

INTERNATIONAL AND NATIONAL CLINICAL TRIALS:

Indication of Trial

Clinical Phase of Trial (I-IV)

Role in Trial (e.g. Investigator, Co-Investigator)

Status (Ongoing/

Completed)

Ticagrelor with Aspirin or alone in high risk patients after coronary intervention

Phase III

Principal Investigator

Ongoing

A randomized double-blind placebo-controlled trial for the evaluation of a polycap, low dose aspirin and vitamin D supplementation in primary prevention

Phase III

Co- Investigator

Ongoing

A Multinational, Randomised, Double-Blind, Placebo controlled Trial to Evaluate the Effect of  Ticagrelor 60 mg twice daily  on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus

Phase III

Co-Investigator

Ongoing

A Multicenter,  Randomized,  Double-Blind, Placebo-Controlled Trial  to  Evaluate  the  Effect  of Dapagliflozin  10  mg  Once  Daily  on the Incidence  of Cardiovascular  Death,  Myocardial Infarction  or Ischemic Stroke in  Patients  with Type  2 Diabetes

Phase III

Co-Investigator

Ongoing

A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate dual antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting

Phase III

Co- Investigator

Ongoing

A non-interventional prospective observational Study to Understand the usage pattern of Ticagrelor in Indian patients with acute coronary syndrome

Registry

Co-Investigator

Ongoing

Asian sudden cardiac death in Heart Failure

Registry

Co-Investigator

Ongoing

Pulmonary Atrial Hypertension

Phase III

Co- Investigator

Ongoing

A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study, Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus

Phase III

Co-Investigator

Ongoing

A prospective study to investigate safety and effectiveness of M’Sure-S (Sirolimus Eluting Coronary Stent)

Registry

Co-Investigator

Ongoing

To Evaluate The Role Of Radiation Protection Technology (CardiotrapTM) In Improving Radiation Safety In Diagnostic And Interventional Percutaneous Cardiology Procedures.

Investigator Initiated Study

Co-Investigator

Ongoing

Safety and Efficacy of Axiostat hemostatic dressing on radial access after percutaneous procedure: A comparative open label study.

Investigator Initiated Study

Co-Investigator

Ongoing

Sinus node dysfunction registry phase 1.

Registry

Co-Investigator

Ongoing

Sinus node dysfunction registry phase 2.

Registry

Co-Investigator

Ongoing

CRDM implantable cardiac device long term registry.

Phase IV.

Co-investigator

Ongoing

IdeNtifying High riSk Patients Post Myocardial Infarction with REduced Left Ventricular Function using External Loop Recorders

Phase IV

Co-Investigator

Ongoing

Improve sudden cardiac arrest study

Phase IV

Co-Investigator

Ongoing

International Registry to assess mEdical Practice with lOngitudinal obseRvation for Treatment of Heart Failure

Phase IV

Co-Investigator

Ongoing

A Multicenter, Randomized, Double-blind, Placebo-controlled Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease.

Phase III

Co-Investigator

Completed

Investigate the association between HR and prognosis of patients with CAD treated with bisoprolol

Phase IV

Co- Investigator

Completed

Platelet inhibition in Acute Coronary Syndromes

Phase III

Co- Investigator

Completed

New Guide wire for Crossing Total Occlusions in Coronary Arteries

First–in-man

Co- Investigator

Completed

Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes.

Phase II

Co- Investigator

Completed

Newly Diagnosed ACS and T2DM

Phase III

Co-Investigator

Completed

Registry of Atrial Fibrillation: Patient Characteristics and Clinical Management Practices

Phase IV

Co- Investigator

Completed

Unstable Angina/Non ST Segment Elevation Myocardial Infarction Scheduled to Undergo an Early Invasive Strategy

Phase III

Co-Investigator

Completed

Observational study of lipid profiles and treatment at presentation and after 12 weeks of statin therapy among Indian adults presenting with first coronary event

Phase IV

Co-Investigator

Completed

Long term follow up of antithrombotic management patterns In Acute Coronary Syndrome patients in Asia

Phase IV

Co-Investigator

Completed

Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 mg vs. Atorvastatin 20 mg (Following Up Titration) in Patients with Primary Hypercholesterolemia Or Combined Dyslipidaemia

Phase III

Co-Investigator

Completed

To evaluate the safety of the Neovasc Reducer™ in the treatment of Ischemic heart Disease (IHD), controlled narrowing of the coronary sinus

Phase III

Co-Investigator

Completed

Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal (REMON Device)

Phase III

Co-Investigator

Completed

Flow improvement in patients with Acute Myocardial Infarction undergoing either conventional stenting or a strategy of primary aspiration followed by stenting using the Export® Aspiration Catheter: a Prospective, Randomized, Controlled Study

Phase III

Co-Investigator

Completed

To Evaluate the ‘Real World’ Clinical Performance of the Medtronic Endeavor™ ABT-578 Eluting Coronary Stent System.

Phase III

Co-Investigator

Completed

Randomized Evaluation of Long term anticoagulant therapy comparing Efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, Parallel group, Non-inferiority trial.

Phase III

Co-Investigator

Completed

Open label, long-Term (1year) extension study of Pitavastatin 4 mg QD in Patients with Primary Hypercholesterolemia or combined Dyslipidemia

Phase III

Co-Investigator

Completed

The e-SELECT Registry : A Multicenter Post Marketing Survelliance

Phase IV

Co-Investigator

Completed

Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non – ST-segment Elevation Acute Coronary Syndrome (EARLY ACS)

Phase III

Co-Investigator

Completed

A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and safety study of AZD6140 Compares with Clopidogrel for prevention of Vascular Events in patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO – A study of PLATelet inhibition and Patient Outcomes.]

Phase III

Co-Investigator

Completed

Randomized, multinational, double-blind study, comparing a high loading dose regimen of Clopidogrel versus standard dose in patients with unstable angina or non-ST segment elevation myocardial infarction managed with an early invasive strategy

Phase III

Co-Investigator

Completed

A Randomized, double blind, Placebo-Controlled, Multicenter, Parallel Study Assessing the Efficacy, Safety, and Dose Response of Ramipril for the Treatment of Hypertension in Children and Adolescents

Phase III

Co-Investigator

Completed

Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation: Active controlled randomized double blind parallel  arm study to evaluate efficacy and safety of Apixaban in subject with  non valvular Atrial fibrillation

Phase III

Co-Investigator

Completed

Multicenter, Randomized, double-blind – dummy, Parallel-group, Non-inferiority Trial Comparing the Efficacy and Safety of Once – daily oral Rivaroxabab (BAY 59 – 7939) with Adjusted – dose oral Warfarin for the prevention of Stroke and Non-central-nervous-system systemic embolism in Subjects with Non-valvular Atrial Fibrillation

Phase III

Co-Investigator

Completed

Patient Related Outcomes with Endeavor versus Cypher stenting Trial: Prospective, multicenter, randomized, two-arm, open-label trial

Phase III

Co-Investigator

Completed

A clinical trial comparing Cangrelor to Clopidogrel in subject who require Percutaneous Coronary Intervention

Phase III

Co-Investigator

Completed

A clinical Trial comparing treatment with Cangrelor (in combination with usual care) to usual care in subjects who require Percutaneous Coronary Intervention

Phase III

Co-Investigator

Completed

Evaluation of the anti-anginal efficacy

Phase III

Co-Investigator

Completed

Randomized Dabigatran Etexilate dose finding study in patients with acute coronary syndromes post index Event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel: Multi-centre, prospective, placebo controlled, group dose escalation trial

Phase III

Co-Investigator

Completed

A Multicenter, Randomized, parallel-group efficacy superiority study in hospitalize medically ill patients comparing rivaroxaban with Enoxaparin

Phase III

Co-Investigator

Completed

A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjusted-dose warfarin in the prevention of stroke and systemic thromboembolic events in patient with atrial fibrillation

Phase III

Co-Investigator

Completed

FREEDOM UT – 15C Studies (TDE-PH-302 and TDE-PH-304) conducted by United Therapeutics.

Phase III

Co-Investigator

Completed

Pilot study to evaluate the safety & performance or the diamond back 360TM orbit Atherectomy system in treating de-NOVO calcified coronary lesions – orbit -1

Phase III

Co-Investigator

Completed

CV 185-048: A Phase 3, Active (Aspirin) Controlled, Randomized, Double-Blind, Parallel arm Study to Evaluate the Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Phase III

Co-Investigator

Completed

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction  and Anemia – 20050222 Amendment 1.

Phase III

Co-Investigator

Completed

A Phase II, double-blind, Randomized, Placebo-controlled study of the safety and Efficacy of TAK-442 in subjects with Acute Coronary Syndrome.

Phase III

Co-Investigator

Completed

A Randomized, Double-Blind Placebo controlled study of the safety and tolerability of E5555 and its effect on clinical event and biomarkers in patient with Non ST segment Elevation Acute Coronary Syndrome.

Phase III

Co-Investigator

Completed

Evaluation of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a Patient Population with Long Lesion(s) and/or Dual Vessels in Asia .A Prospective, Multi-center, Non-randomized Study

Registry

Co-Investigator

Ongoing

Randomized, Double Blind, Placebo Controlled, Event Driven, Multi-Center Study To Evaluate The Efficacy And Safety Of Rivaroxaban In Subjects With Recent ACS.

Phase III

Co-Investigator

Completed

A Phase 3, Multi Center, Randomized, Double Blind, Placebo Controlled, Safety And Efficacy Study Of Sitaxsentan Sodium In Subjects With Pulmonary Arterial Hypertension

Phase III

Co-Investigator

Completed

A Phase 3, Multi Center, Open Label Study To Evaluate The Long Term Safety Of Monotherapy Sitaxsentan Sodium And Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension.

Phase III

Co-Investigator

Completed

A Phase 3, Multi Center, Randomized, Double Blind, Efficacy And Safety Study Of Monotherapy Sitaxsentan Sodium Versus Combination Therapy With Sitaxsentan Sodium and Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension Who Have Completed Study B1321001.

Phase III

Co-Investigator

Completed

A Clinical Outcome Study Of Darapladib Versus Placebo In Subjects With Chronic Coronary Heart Disease To Compare The Incidence Of Major Adverse Cardiovascular Event. (MACE)

Phase III

Co-Investigator

Completed

A Prospective Study Evaluating The Safety Of Two Regimens Of Adjustive Intravenous UFH PCI In High Risk Patients With UA/NSTEMI Initially Treated With Subcutaneous Fondaparinux And Referred For Early Coronary Angiography.

Phase III

Co-Investigator

Completed

A Randomized, Double Blind, Multi Centric, Placebo Controlled, Single Dose, Phase I/II Study Assessing The Safety And Efficacy Of Intravenous Ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cell In Patients With ST Elevated Acute MI (STEMI) Patient.

Phase III

Principal Investigator

Completed

A Randomized, Double Blind, Placebo Controlled, Multi Center and Parallel Group Study of the Safety, Tolerability, and Efficacy of YM150 in combination with  Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes.

Phase III

Co-Investigator

Completed

A phase 3, multi centre, placebo controlled, randomized, double blind, 12 week study with an open label extension to evaluate the efficacy And safety of AMR101 in patients with fasting triglyceride levels > 500 mg/dl and < 2000 mg/dl.

Phase III

Co-Investigator

Completed

A Phase 3, Randomized, Double-blind, Evaluation of the safety and Efficacy of Apixaban in subjects with a Recent Acute Coronary Syndrome

Phase III

Co-Investigator

Completed

South Asian Systolic Heart Failure Registry.

Phase IV

Co-Investigator

Completed

TRAC HF: Ambulatory Monitoring Using External Physiological Sensors in Heart Failure Patients.

Phase III

Co-Investigator

Completed

DOT-HF- Diagnostic Outcome Trial in Heart Failure.

Phase IV

Co-Investigator

Completed

T-BEST-D: Temporary Bronchial Epicardial Stimulation – Defibrillation Clinical Study Version dated: June 28, 2009.

Phase IV

Co-Investigator

Completed

Cardiovascular outcomes study  to evaluate the potential of aleglitazar to reduce cardiovascular  risk in patients with  recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)

Phase III

Co-Investigator

Completed

A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).

Phase III

Co-Investigator

Completed

A Randomized ,double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infract size, and cardiac function in subjects with myocardial infarction without ST segment elevation.

Phase III

Co-Investigator

Completed

A Randomized. Double-Blind, Parallel, Placebo-Controlled, Multicenter Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus. The CANVAS Trial (Canagliflozin Cardiovascular Assessment Study)

Phase III

Co-Investigator

Ongoing

A prospective, non-randomized, multi-center, post-market, global clinical  trial to assess left-heart lead implant and complication rate using the  Medtronic Attain Family of left-heart leads and delivery catheters.

Phase IV

Co-Investigator

Completed

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase IV Trial to Evaluate the effect of Sexagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in patient with Type 2 Diabetes)

Phase III

Co-Investigator

Completed

Clinical Outcome of Pacemaker patients according to pacing Modality and primary Indications.

Phase IV

Co-Investigator

Completed

The Pain free SST (Smart Shock Technology) clinical Study.

Phase IV

Co-Investigator

Completed

To evaluate the efficacy and safety of BIVAFLO® as an adjunctive therapy during PCI in moderate-high risk ACS patients with provisional GP IIb/IIIa inhibitors use.

Registry

Co-Investigator

Completed

The COREL C Registry : A multicentre Post marketing Survelliance for clinical and angiographic evaluation of Corel C stent

Registry

Co-Investigator

Trial completed

A randomized double blind controlled trial of the efficacy And safety of POLYCAP Vs. its components in subjects With at least one additional cardiovascular risk factor

Co-Investigator

Trial completed

A phase III, open label, multicentric, parallel group, Randomized study to evaluate the safety and efficacy of Abciximab in Indian patients scheduled for Percutaneous Coronary Intervention.

Phase III

Co-Investigator

Trial completed

(1) A randomized, double blind parallel group, prospective dose ranging study of ZYH 1 with an open fenofibrate arm to evaluate the efficacy on Dyslipidemia in patients without diabetes  Protocol No. 2001 Ver: 01 (2) A randomized, double blind parallel group, prospective dose ranging study of ZYH1 with an open pioglitazone arm to evaluate the efficacy on Dyslipidemia in patients with diabetes Protocol No. 2003 Ver: 02 (3) A randomized, double blind parallel group, prospective dose ranging study of ZYH 1 with an open pioglitazone arm to evaluate the efficacy on Dyslipidemia in patients with impaired glucose test Protocol No.2004 Ver: 02

Co-Investigator

Trial completed

PROCEDURES

DONE

ASSISTED

Congenital Echo

>10000

                    

Adult Echo/TEE

>10000

Coronary angiogram/cath

>10000

112

PTCA

>5000

231

BMV/BPV/BAV/Coactoplasty

>500

103/9/6/6

ASD/PDA Device closure

>100

19/7

Temporary Pacemaker

Implantation

>1000

31

Permanent Pacemaker

Implantation

>200

50

PTA

>100

55

  References:

  1. Dr Gilles Montalescot

            Institut De Cardiologie

            Department De Cardiologie Medicale

            Assistance Public Hopitaux

            PITIE-SALPETRIERE University Hopital   

50/52, Bouleverd Vincent Auriol

     75651  PARIS CEDEX 13 FRANCE

     

  1. Dr. V. Jacob Jose, MD DM(Card), FCCP MS(USA) FACC

Head and Professor of Department of Cardiology,

Christian Medical College and Hospital,

Vellore 632 004

Tamil Nadu – INDIA

  1. Dr. George Joseph, MD DM(Card)

Head and Professor of Department of Cardiology, Unit I

Christian Medical College and Hospital,

Vellore 632 004

Tamil Nadu – INDIA

                                               ***

 

Your doctor believes in patient education. You will find a list of patient education videos here soon to get to know both your doctor and the disease better. CIMS Hospital in Ahmedabad and your doctor believes in transferring as much patient education knowledge as possible and is the process of uploading tons of patient education videos that can help you understand the disease or problems better.

 

 

 

Forms

Organ Donation Registration Form
Job Application Form

Your vote counts at CIMS Hospital, so here is our monthly question to you on whether or not the hospital should offer free internet to it's guests or whether it's not needed since everyone has an internet connection on their phone.

Do certifications like NABH, NABL or JCI help give you confidence in a hospital ?

How important is free internet (wifi) in a hospital ?

CIMS Hospital was awarded being the best hospital in Gujarat for 2019 by the International Health Care Awards.

CIMS Hospital is a 350-bedded, multi-super speciality and regarded one of the best multi-speciality hospitals of Ahmedabad in Gujarat providing a range of diagnostic and treatment services.

CIMS Hospital has been awarded best hospital for quality in service delivery award at the ABP News presents Healthcare Leadership Awards 2015 held at Mumbai.

CIMS Hospital has been recognized as the Times Health Icon 2018 for being the best Hospital for Oncology and Critical Care. CIMS Hospital also was rated the Best Multispecialty Hospital in Gujarat at the International Healthcare Awards, 2018 held in Delhi.

CIMS Hospital provides world-class treatment and healthcare services in India and the leading heart hospital in Ahmedabad, Gujarat. CIMS Hospital offers the highest quality services and offers treatment to most diseases and medical problems with one of the highest success rates in India.

CIMS Hospital
Care Institute of Medical Sciences
Off Science City Road, Sola, Ahmedabad – 380060
Gujarat, INDIA

24x7 Helpline +91 70 69 00 00 00
Phone: +91 79 2771 2771 or 72
Fax: +91 79 2771 2770
Mobile: +91 98250 66664 or +91 98250 66668
Ambulance: +91 98244 50000
Email: info@cims.org